Zyprexa Relprevv

Delirium, Delusional Parasitosis, Schizophrenia + 11 more
Treatment
8 FDA approvals
20 Active Studies for Zyprexa Relprevv

What is Zyprexa Relprevv

OlanzapineThe Generic name of this drug
Treatment SummaryOlanzapine is an antipsychotic medication that belongs to a class of drugs called atypical antipsychotics. It was approved for use in the United States in 1996 and is known to be effective in treating mental illnesses with fewer side effects and drug interactions compared to other antipsychotics. Olanzapine is very similar to the drug clozapine, with two additional methyl groups and no chloride content.
Zyprexais the brand name
image of different drug pills on a surface
Zyprexa Relprevv Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zyprexa
Olanzapine
1996
546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 8 uses which include Mental Depression and Bipolar Disorder .
Mental Depression
Used to treat Acute Depressive Episode in combination with Fluoxetine
Bipolar Disorder
Used to treat Bipolar 1 Disorder in combination with Fluoxetine
Bipolar Disorder
Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation
Unipolar Depression
Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine
Bipolar Disorder With Manic or Mixed Episodes
Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation
Bipolar 1 Disorder
Used to treat Bipolar 1 Disorder in combination with Fluoxetine
Acute Depressive Episode
Used to treat Acute Depressive Episode in combination with Fluoxetine
Major depressive disorder, recurrent episode
Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Effectiveness

How Zyprexa Relprevv Affects PatientsOlanzapine works by targeting two different receptors in the brain - the dopamine D2 receptor and the serotonin 5HT2A receptor. This action has been found to be effective in reducing symptoms of schizophrenia, bipolar disorder in adults and acute episodes of bipolar disorder in adolescents. It has also been demonstrated to be successful in reducing chemotherapy-induced nausea and vomiting. Studies have shown that olanzapine can produce a complete response in 84% of individuals and control nausea and vomiting for over 80%.
How Zyprexa Relprevv works in the bodyOlanzapine works by blocking various receptors in the brain, including dopamine and serotonin receptors. Blocking dopamine receptors in the mesolimbic pathway is key to its activity. Olanzapine binds to these receptors and makes it harder for dopamine to activate them. It also affects serotonin 5HT2A receptors in the frontal cortex, which helps reduce unwanted side effects.

When to interrupt dosage

The suggested dosage of Zyprexa Relprevv is contingent upon the diagnosed affliction, including Schizophrenia, Bipolar Disorder and Delirium. The amount of dosage likewise varies, in line with the technique of delivery (e.g. Kit - Intramuscular or Tablet, film coated - Oral) as noted in the below table.
Condition
Dosage
Administration
Delirium
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Schizophrenia
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Schizophrenia
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Post Traumatic Stress Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Tourette Syndrome
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Mental Depression
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Acute Agitation
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Unipolar Depression
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Acute Coryza
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Delusional Parasitosis
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Alzheimer's Disease
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular
Bipolar Disorder
2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL
, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release, Kit, Kit - Intramuscular

Warnings

There are 20 known major drug interactions with Zyprexa Relprevv.
Common Zyprexa Relprevv Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.
Acepromazine
Major
Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.
Alfuzosin
Major
Olanzapine may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Olanzapine may increase the antipsychotic activities of Amisulpride.
Zyprexa Relprevv Toxicity & Overdose RiskTaking too much olanzapine can cause drowsiness, dilated pupils, slow breathing, low blood pressure, muscle stiffness, and dry mouth. Clinical trials have reported the maximum dose of olanzapine to be 300mg, which can cause slurred speech and drowsiness. However, reports of more serious side effects after taking higher doses of olanzapine, such as agitation, difficulty speaking, fast heartbeat, muscle stiffness, and loss of consciousness, have been noted. In one case, a person died after taking 450mg of olanzapine. Treatment for an overdose may include providing oxygen

Zyprexa Relprevv Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyprexa Relprevv?

578 active clinical trials are exploring the potential of Zyprexa Relprevv in the management of Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.
Condition
Clinical Trials
Trial Phases
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Post Traumatic Stress Disorder
239 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3, Phase 4, Phase 2, Phase 1
Bipolar Disorder
0 Actively Recruiting
Schizophrenia
31 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4
Mental Depression
2 Actively Recruiting
Phase 2, Not Applicable
Delirium
26 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1
Unipolar Depression
48 Actively Recruiting
Not Applicable, Phase 4, Early Phase 1, Phase 3, Phase 2, Phase 1
Bipolar Disorder
0 Actively Recruiting
Bipolar Disorder
0 Actively Recruiting
Delusional Parasitosis
0 Actively Recruiting
Alzheimer's Disease
39 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1
Acute Coryza
1 Actively Recruiting
Not Applicable
Acute Agitation
0 Actively Recruiting
Tourette Syndrome
0 Actively Recruiting

Patient Q&A Section about zyprexa relprevv

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does Zyprexa IM injection last?

"Olanzapine extended-release injection is typically given once every 2 to 4 weeks. Olanzapine extended-release injection may help manage your symptoms but will not cure your condition."

Answered by AI

Is Zyprexa Relprevv still available?

"Because of the potential risks, ZYPREXA RELPREVV is only available through a restricted distribution program called the ZYPREXA RELPREVV Patient Care Program. This program requires enrollment of the prescriber, healthcare facility, patient, and pharmacy. [see Dosage and Administration (2.1), Warnings and Precautions (5.1, 5.2), Overdosage (10.2), and ..."

Answered by AI

How do you administer Zyprexa Relprevv?

"Zyprexa Relprevv should be administered by a healthcare professional every 2 to 4 weeks by deep intramuscular gluteal injection using a 19-gauge, 1.5-inch needle. Following insertion of the needle into the muscle, the healthcare professional should aspirate for several seconds to ensure that no blood is drawn into the syringe."

Answered by AI

How long does Zyprexa Relprevv last?

"Olanzapine as a pamoate monohydrate is a long-lasting injectable or depot form of olanzapine that provides another option for maintaining treatment of schizophrenia. It is administered by deep intramuscular gluteal injection only, every 2 weeks or every 4 weeks."

Answered by AI

Clinical Trials for Zyprexa Relprevv

Image of Stony Brook University Hospital in Stony Brook, United States.

Transauricular Vagus Nerve Stimulation for Delirium

18+
All Sexes
Stony Brook, NY
The goal of this clinical trial is to test whether a non-invasive device called transauricular vagus nerve stimulation (taVNS) is safe, practical, and potentially helpful for patients in the hospital who develop delirium. Delirium is a state of confusion that often happens to people in the hospital who are sick or hurt. It can cause agitation, trouble paying attention and difficulty understanding what is happening. Delirium may slow overall recovery. This study will focus on feasibility and safety. Researchers want to learn whether taVNS can be given safely to critically-ill patients, whether patients and staff can tolerate the treatments, and whether the device produces measurable changes in brain activity and brain oxygen levels. The main questions this study aims to answer are: * Is it possible to deliver taVNS safely and consistently to patients in the ICU who have delirium? * Do patients tolerate the device without significant side effects or complications? * Does taVNS cause short-term changes in brain signals and oxygen levels that may suggest effects on brain function? This is an early feasibility study and there is no randomization or placebo group. All patients enrolled will receive taVNS in addition to their usual hospital care for delirium. What participants will do: * Be identified by their hospital care team and have a confirmed diagnosis of delirium. * Provide consent (or have a legally authorized representative provide consent if the patient cannot.) * Undergo brief assessments of thinking and attention (for example, the CAM-ICU test.) * Receive taVNS treatment using a small clip electrode placed on the ear. * The device sends gentle electrical pulses to the nerve in the ear. * Each session lasts about 30 minutes, given twice per day (morning and evening, with at least 6 hours between sessions). * Treatment can continue for up to 7 days while the patient is in the ICU. * Be monitored during and after each session. The study team will check vital signs, examine the ear for irritation, and ask about any discomfort. * On the first day, researchers will also record brain signals (EEG) and brain oxygen levels before and during stimulation using FDA-approved hospital monitoring devices. Possible risks and discomforts: * Mild side effects are possible, such as tingling, a tickling or pricking feeling in the ear, or temporary skin redness where the clip is placed. * Serious side effects are not expected, but all patients will be closely monitored during and after each session to ensure safety. Possible benefits: • Patients may or may not experience personal benefit. The main benefit is helping researchers learn whether this treatment approach is safe and practical. In the future, taVNS could potentially become a new tool to help treat or prevent delirium in hospitalized patients. Study size and duration: * The study will enroll a limited number of ICU patients with delirium at Stony Brook University Hospital. * Patients may take part for up to 7 days while hospitalized. Who can join: * Right-handed, adult patients in the ICU who are diagnosed with delirium. * People with certain medical conditions (such as brain bleeds, new strokes, pacemakers or other contraindications) may not be able to participate, for safety reasons.
Recruiting
Has No Placebo
Stony Brook University HospitalIsadora Botwinick, MD
Image of University of Rochester Medical Center in Rochester, United States.

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

18+
All Sexes
Rochester, NY
The goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A desperate need for a rapid acting antidepressant drug (RAAD) is needed to help improve quality of life for people with TRD. Ketamine has been shown to be a RAAD, and esketamine (a form of ketamine) was approved by the FDA to treat TRD. Ketamine has been known to cause dissociative experiences, that can lead to an increase in the "Openness to Experience" personality trait and psychological flexibility that occurs at "peak experience". This has been shown to improve mental health conditions and lower suicide risk. Our study aims to further understand if there is a connection between this new change of mind and changes in brain activity. Ketamine has been shown to improve brain plasticity as well, specifically in the frontolimbic region of the brain, an area associated with depression. We are analyzing the brain using functional magnetic resonance imaging (fMRI), a method used to measure brain activity. The frontolimbic region is also associated with cognitive flexibility and emotional processing, an important hurdle in treating TRD. Due to this, we are pairing the ketamine treatment with psychotherapy sessions, to guide the processing experience, which can lead to higher emotional flexibility. The main questions this study aims to answer are: * Are frontolimibic plasticity circuitry changes associated with openness to experience and peak experience? * Is it feasible to recruit and retain people through a two-month study? * Is the structure of the study effective for treating TRD? Participants will: * Visit the facilities 6-8 times * Complete 2 MRI brain scans * Complete 3-4 psychotherapy sessions * Receive 1-2 doses of ketamine * Complete online surveys between 3-4 visits
Phase 2
Waitlist Available
University of Rochester Medical Center
Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.Go to Trials
Image of Cohen and Associates in Sarasota, United States.

NRX-101 + TMS for Treatment Resistant Depression

18 - 80
All Sexes
Sarasota, FL
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes. DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When the AMPA one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week. This trial will compare response and remission at six weeks following Transcranial Magnetic Stimulation + D-cycloserine vs. TMS+placebo.
Phase 2 & 3
Waitlist Available
Cohen and AssociatesNeuroRx, Inc.
Image of Weill Cornell Medicine in New York, United States.

Integrated Treatment for PTSD and Chronic Pain

18+
All Sexes
New York, NY
Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions. Gold standard treatments exist for both PTSD (e.g., Prolonged Exposure; PE) and chronic pain (e.g., Cognitive Behavioral Therapy for Chronic Pain; CBT-CP) and are generally offered sequentially (i.e., one at a time for the condition that is most prominent). Treating these conditions separately may overlook their interconnected nature, which may reduce efficacy and increase dropout. Thus, there is a need for an intervention to target both simultaneously, which may be more effective and efficient than treating conditions sequentially. This is a single-arm pilot study to assess the feasibility and acceptability of an integrated treatment for adults with comorbid PTSD and chronic pain. The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment draws from modules in PE and CBT-CP including psychoeducation, exposure to feared/avoided situations and activities, processing of exposures, behavioral activation, breathing and relaxation techniques, sleep hygiene, symptom monitoring, and structured homework assignments. Baseline and post-treatment assessments will be conducted.
Waitlist Available
Has No Placebo
Weill Cornell MedicineJoAnn Difede, PhD
Image of Scottsdale Research Institute in Cave Creek, United States.

Inhaled Cannabis for PTSD

18+
All Sexes
Cave Creek, AZ
The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.
Phase 2
Waitlist Available
Scottsdale Research Institute
Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.Go to Trials
Image of VA Phoenix Healthcare System in Phoenix, United States.

Integrated Health Care for Post-Traumatic Stress Disorder

18+
All Sexes
Phoenix, AZ
The goal of this clinical trial is to determine whether which types of integrative care, meaning a combination of psychotherapy and mind-body interventions, lead to the most changes in functioning among Veterans with posttraumatic stress disorder (PTSD). The main aims are: 1. To evaluate the impact of integrative care approaches on functional outcomes among Veterans with PTSD. 2. To examine factors relevant to the implementation of integrated treatments for PTSD from the perspective of patients, providers and administrators in the VA Healthcare System. Participants will: 1. Complete assessments at the beginning of the study and 12- and 24-weeks later. 2. Engage in 12 weeks of integrated care, with the type being randomly assigned.
Waitlist Available
Has No Placebo
VA Phoenix Healthcare System (+4 Sites)
Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security